International Journal of Clinical Pharmacy

, Volume 34, Issue 1, pp 23–26 | Cite as

Activated protein C in patients with septic shock: a consecutive case series

  • Jens A. Wagner
  • Heiner Langenfeld
  • Luise Klett
  • Stefan StörkEmail author
Short Research Report


Background: The recommendation to restrict the use of activated protein C (APC) to patients with severe sepsis and the highest risk of death originates from large trials that were subject to major exclusion criteria. Objective: To investigate the effect of APC on prognosis in ‘real world’ patients. Method: Consecutive case series at tertiary care hospital including 63 adults with septic shock and multi-organ failure treated with APC (24 mcg/kg/h) for up to 96 h in addition to standard care. Results: Median APACHE score was 35 (quartiles, 29–41), mean number of failing organs was 4 (quartiles, 4–5), and overall 30-day mortality was 48%. Independent predictors of 30-day mortality risk were the number of failing organs and number of antibiotics given. Risk of dying was significantly lower if compared with the mortality rates expected per APACHE II score category (P for trend per 5-point increment <0.001). This association was most prominent in patients with an APACHE II score of 30–44. Intracranial or major bleeding during APC treatment did not occur. Conclusion: These findings support the view that targeting APC treatment to patients with septic shock and a very high risk is a sound and safe approach. However, due to lack of consistent evidence from randomized studies APC was recently removed from the market.


APACHE score Drotrecogin alfa Mortality Organ failure Sepsis 



We like to thank all nurses caring for patients during this study at the Internal Medicine ICU of the University Hospital Würzburg.


No funding was obtained for this study.

Conflicts of interest



  1. 1.
    Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med. 2003;168(2):165–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699–709.PubMedCrossRefGoogle Scholar
  4. 4.
    Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med. 2005;33(10):2266–77.PubMedCrossRefGoogle Scholar
  5. 5.
    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353(13):1332–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296–327.PubMedCrossRefGoogle Scholar
  7. 7.
    Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest. 1992;101(6):1481–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Brierley J, Carcillo JA, Choong K, Cornell T, Decaen A, Deymann A, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009;37(2):666–88.PubMedCrossRefGoogle Scholar
  9. 9.
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE. An evaluation of outcome from intensive care in major medical centers. Ann Intern Med. 1986;104(3):410–8.PubMedGoogle Scholar
  10. 10.
    Holler E, Kolb HJ, Greinix H, Perrotin D, Campilho F, Aversa F, et al. Bleeding events and mortality in SCT patients: a retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD. Bone Marrow Transplant. 2009;43(6):491–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Levy M, Levi M, Williams MD, Antonelli M, Wang D, Mignini MA. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. Intensive Care Med. 2009;35(7):1196–203.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Jens A. Wagner
    • 1
  • Heiner Langenfeld
    • 1
  • Luise Klett
    • 1
  • Stefan Störk
    • 1
    • 2
    Email author
  1. 1.Department of Internal Medicine IUniversity Hospital WürzburgWürzburgGermany
  2. 2.Comprehensive Heart Failure CenterUniversity of WürzburgWürzburgGermany

Personalised recommendations